MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.84
+0.12
+2.01%
Closed 16:00 05/26 EDT
OPEN
6.00
PREV CLOSE
5.73
HIGH
6.00
LOW
5.70
VOLUME
12.25K
TURNOVER
28.08K
52 WEEK HIGH
12.28
52 WEEK LOW
5.01
MARKET CAP
77.11M
P/E (TTM)
-7.0074
1D
5D
1M
3M
1Y
5Y
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences.
PR Newswire · 3d ago
KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childh...
PR Newswire · 05/17 12:00
Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 69% gain
The Kazia Therapeutics Limited ( ASX:KZA ) share price is down a rather concerning 35% in the last month. But that...
Simply Wall St. · 05/17 01:12
Kazia Therapeutics to Present Final Data From Its Paxalisib Phase 2 Study In Glioblastoma At American Society For Clinical Oncology Jun 5, 2022 at 9 a.m.-12 p.m. EDT
Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will
Benzinga · 04/29 15:01
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentati...
PR Newswire · 04/29 15:00
Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer
Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma.
Benzinga · 04/21 14:39
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 04/21 14:15
Kazia Therapeutics Announced Phase II Study of Paxalisib in Glioblastoma Achieved Final Completion; Data to Be Presented at Upcoming Conference
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its phase II study of paxalisib in glioblastoma (NCT03522298) has been successfully completed.
Benzinga · 04/21 09:23
More
No Data
Learn about the latest financial forecast of KZIA. Analyze the recent business situations of Kazia Therapeuti through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KZIA stock price target is 11.25 with a high estimate of 11.25 and a low estimate of 11.25.
High11.25
Average11.25
Low11.25
Current 5.84
EPS
Actual
Estimate
-0.58-0.43-0.29-0.14
2020/12
2020/06
2021/12
2021/06
2022/12
Institutional Holdings
Institutions: 14
Institutional Holdings: 507.34K
% Owned: 3.84%
Shares Outstanding: 13.20M
TypeInstitutionsShares
Increased
1
95
New
3
1.74K
Decreased
4
44.57K
Sold Out
3
56.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman
Iain Ross
Chief Executive Officer/Executive Director
James Garner
Chief Financial Officer
Karen Krumeich
Other
John Friend
Other
Lilischkis Kimberley
Other
Peng Leong
Other
Stephen Palmer
Other
Justine Stehn
Secretary
Kate Hill
Non-Executive Director
Bryce Carmine
Non-Executive Director
Steven Coffey
No Data
No Data
About KZIA
Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The Company entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The Company entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.